Skip to main content
HomeEventsNeuropsychology in the New Era of Alzheimer’s Disease: Biomarkers, APOE, and Disease-Modifying Thera

Events - Event View

Neuropsychology in the New Era of Alzheimer’s Disease: Biomarkers, APOE, and Disease-Modifying Thera

warning If you are a member, please log in to access member benefits, if available. close

Date and Time

Tuesday, October 27, 2026, 7:00 PM until 8:30 PM

Event Contact(s)

MNS ECC
Contact with questions!

Category

Webinars

Registration Info

Registration is required
Payment In Full In Advance Only
Registration modifications are permitted until Monday, October 26, 2026 at 6:00 PM
Registration cancellations will be accepted until Monday, October 26, 2026 at 6:00 PM
Cancellation Policy:
The Massachusetts Neuropsychological Society is committed to providing accessible, high-quality lectures delivered in person and/or as a webinar. Because our organization is a nonprofit, the registration fees and donations we receive directly support our mission. To ensure fairness and transparency, we have established the following credit and cancellation policy: Please note that MNS does not offer cash refunds. We provide credit stored under an MNS account for the amount paid. Credits can be used for future programs or other fees such as membership under the following circumstances: 

WEBINARS
1. Participant Cancellations
Credits:
o Cancellations made up to 7 days after the date of the webinar are eligible for a full credit of the registration fee. Cancellations must be made in writing.

2. Organization Cancellations
If the Massachusetts Neuropsychological Society cancels a webinar for any reason, all registrants will receive a full credit that can be applied to future MNS events or other fees such as membership.

3. Technical Issues
Participant Issues: Credits are not issued for technical problems on a participant’s end (e.g., internet outages, device malfunctions). We encourage registrants to test their systems in advance.

Organizer Issues: If significant technical difficulties prevent the webinar from taking place, registrants will receive a full credit.
 
4. Donations
Contributions made in addition to registration fees are considered donations and are non-refundable.

5. How to Request a Credit
All credits, cancellation, or transfer requests must be submitted in writing to admin@massneuropsych.org. Please allow 7–10 business days for processing.

About this event

Presented by: 
Daniel R. Seichepine, Ph.D.

About the Webinar: 

Recent advances in blood-based biomarkers, genetic testing, and disease-modifying therapies are transforming how Alzheimer's disease is diagnosed and treated. These developments also raise important questions about the evolving role of clinical neuropsychologists.
This presentation will review emerging Alzheimer's disease biomarkers, the clinical significance of APOE genotype, and the benefits and limitations of anti-amyloid monoclonal antibody therapies. Particular emphasis will be placed on how neuropsychologists can contribute to early identification, differential diagnosis, and treatment eligibility decisions. Practical examples from clinical evaluations will illustrate how these advances can be integrated into neuropsychological practice.



Learning Objectives:
By the end of this presentation, participants will be able to:
  1. Identify the clinical applications and limitations of emerging blood-based biomarkers for Alzheimer's disease.
  2. Identify key benefits and risks of anti-amyloid monoclonal antibody therapies, including the role of APOE genotype in treatment-related risk assessment.
  3. Identify ways neuropsychological assessment can contribute to the early diagnosis of Alzheimer's disease and multidisciplinary decisions regarding treatment eligibility.


About the speaker:
Daniel R. Seichepine, Ph.D., is an Associate Professor of Clinical Psychology at William James College and a clinical neuropsychologist practicing in Massachusetts and New Hampshire. He is also the owner of Next Step Neuropsychology, a private practice specializing in the evaluation of cognitive and neurological disorders.
Dr. Seichepine earned his Ph.D. from Boston University and completed his postdoctoral training at the Boston University Alzheimer's Disease Center. Before joining William James College, he spent 12 years on the faculty at the University of New Hampshire.
His clinical and research interests include Alzheimer's disease, cognitive aging, and traumatic brain injury. For more than a decade, he has served as a consultant on international clinical trials investigating treatments for Alzheimer's and Parkinson's diseases, including trials evaluating disease-modifying therapies for Alzheimer's disease. He regularly presents to professional and public audiences on advances in Alzheimer's disease diagnosis and treatment.

 



The Massachusetts Neuropsychological Society is approved by the American Psychological Association to sponsor continuing education for psychologists. The Massachusetts Neuropsychological Society maintains responsibility for this program and its content.

Number of People Who Will Attend

Guest
$40.00
Non-Member Student/Post-Doctoral Fellow/Intern
(No Fee)
Register Now